Perspective Therapeutics CATX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $84.22M+102% | $41.64M+95.4% | $21.31M+725% | $2.58M— | ||
| $30.23M+13.6% | $26.61M+26.3% | $21.06M+218% | $6.62M+41.1% | ||
| $114.45M+23.9% | $92.34M+118% | $42.38M+253% | $12.01M+40.2% | ||
| -$113.56M-25.0% | -$90.89M-122% | -$40.94M-432% | -$7.69M— | ||
| $9.14M-12.6% | $10.46M+1,153% | $835K— | —— | ||
| -$104.43M-29.8% | -$80.43M-101% | -$40.11M— | —— | ||
| -$103.12M-30.1% | -$79.28M-70.5% | -$46.51M-521% | -$7.49M-32.5% | ||
| -$1.40-12.0% | -$1.25+25.6% | -$1.68— | —— | ||
| -$110.31M-24.5% | -$88.58M-122% | -$39.96M— | —— | ||
| -$113.56M-25.0% | -$90.89M-122% | -$40.94M-432% | -$7.69M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Perspective Therapeutics's revenue?
- Perspective Therapeutics (CATX) generated $10.0M in revenue over the trailing twelve months, up 0.5% year over year.
- Is Perspective Therapeutics profitable?
- Perspective Therapeutics is not currently profitable: it reported a net loss of $111.1M over the trailing twelve months, a -218.4% net margin.
- What are Perspective Therapeutics's profit margins?
- Gross margin is 33.1% and operating margin is -292.7%, with a -218.4% net margin.
- What is Perspective Therapeutics's earnings per share?
- Perspective Therapeutics's diluted EPS over the trailing twelve months is $-1.40.
- Where does Perspective Therapeutics's income statement data come from?
- Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
